ArticleScientific reports2025
AI-assisted identification of innovative phytochemicals from Aizoon canariense aimed at brachyury protein in chordoma: a computational strategy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Chordoma is an unique and aggressive bone malignancy along with limited therapeutic options, largely due to the undruggable nature of the TBXT oncoprotein. In this study, we employed an AI-assisted drug discovery approach to optimize β-sitosterol from Aizoon canariense against TBXT. Among the generated analogs, Artificial Intelligence Ligand 2 demonstrated strong inhibitory potential, showing a stable binding free energy of - 81.09 kcal/mol and maintaining conformational stability during a 500 ns molecular dynamics simulation. Key pharmacokinetic parameters revealed blood-brain barrier permeability, high gastrointestinal absorption as well as compliance with Lipinski's rules, while toxicity evaluation predicted moderate acute toxicity (LD₅₀ = 800 mg/kg, Class IV) with no major systemic risks. Density Functional Theory analysis confirmed molecular stability and reactivity suitable for biological interactions. Overall, these results highlight AI-Ligand 2 as a promising phytochemical derivative for targeting TBXT in chordoma, providing a foundation for future experimental validation and preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.